Transcat TRNS 深 沪
已收盘 08-01 16:00:00 美东时间
74.55
-1.880
-2.46%
华盛通- 最 高76.53
- 今 开76.14
- 成交量 6.36万股
- 最 低 73.275
- 昨 收 76.43
- 总市值 6.95亿
- 52周最高 133.7199
- 市盈率 静 47.53
- 换手率 0.68%
- 52周最低 67.555
- 委 比 42.36%
- 总股本 931.77万
- 历史最高 147.115
- 量 比 0.99
- 振 幅 4.26%
- 历史最低 4.97
- 每 手 1
- 风险率 12.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance
Edwards Lifesciences beat Q2 estimates and raised its 2025 sales outlook as TAVR and TMTT segments drove double-digit revenue growth.
07-26 01:49
Procept BioRobotics down after CEO retirement
Shares of Procept BioRobotics (NASDAQ:PRCT) fell ~9% on Friday after the surgical robotics company announced that its CEO, Reza Zadno, would retire effective Sept. 1, and Larry Wood, a member of the b...
07-25 23:23
PROCEPT BioRobotics Announces Preliminary Q2 Revenue Of ~$79.2M
SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) ("the Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology,
07-25 06:05
Transcat Director Charles Hadeed Announces Retirement
Transcat ( ($TRNS) ) has issued an update. On July 16, 2025, Charles P. Hadeed ...
07-23 04:52
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Lake Street Initiates Coverage On Transcat with Buy Rating, Announces Price Target of $105
Lake Street initiates coverage on Transcat (NASDAQ:TRNS) with a Buy rating and announces Price Target of $105.
07-11 04:48
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
HC Wainwright & Co. Reiterates Buy on Transcat, Maintains $116 Price Target
HC Wainwright & Co. analyst Scott Buck reiterates Transcat (NASDAQ:TRNS) with a Buy and maintains $116 price target.
06-25 18:23
FDA Approves Abbott's Tendyne Transcatheter Mitral Valve Replacement System To Treat People With Mitral Valve Disease
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC)Tendyne offers a new treatment
05-27 21:03
